Clinical Trial Update: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 safety and tolerability study of the investigational compound JNJ-54861911 in participants with early Alzheimer’s disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• JNJ-54861911

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED